Page results
-
A healthcare project aimed at homeless people and delivered by UCLH has been specially commended in this year’s London Homelessness Awards.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
This page offers advice to patients who are feeling sick.
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 29 January 2025.
-
Short videos on managing cancer pain, cancer-related fatigue and improving sleep
-
This page provides information for pregnant women with Inflammatory Bowel Disease.
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
-
This information is for UCLH patients with cancer or a blood condition who are being offered a PICC (peripherally inserted central catheter).
-
Learn more about how UCLH celebrated Research Open Day this month.
File results
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0224 - Patients prescribed medical equipment for use in the home
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0220 - Internally produced patient information leaflets
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment